Evicenter
P&T meetings

Tovecimig (CTX-009)

Second-line advanced biliary tract cancer

Also known as ABL001
Last updated
89 sources

Product information and disease descriptionProduct descriptionProduct informationPharmacology

Pharmacodynamics

3 evidence topics · 2 sources

Preclinical antitumor activity in gastric and colon cancer xenograft models

“Both bispecific antibodies, mABL001 and ABL001, inhibited tumor progression in the tested xenograft models at doses ranging from 1 to 6.5 mg/kg” (opens the source at this quote in a new tab)

“The anti-cancer effects of mABL001 or ABL001 monotherapy were calculated as %TGI ranging from 27.4% to 57.2%, depending on the doses of mABL001 or ABL001 and cancer cell lines in xenograft models” (opens the source at this quote in a new tab)

Effect on tumor vasculature and on target expression in tumor endothelium

“Based on the results of immunohistochemical analysis of tumor blood vessels, the expression levels of VEGFR-2 and DLL4, dual targets of ABL001, were markedly reduced in tumor endothelial cells after ABL001 treatment compared to that of CD31, a conventional endothelial cell marker.” (opens the source at this quote in a new tab)

“The combination treatment synergistically inhibited tumor progression compared to each monotherapy. More tumor vessel regression and apoptotic tumor cell induction were observed in tumors treated with the combination therapy, which might be due to tumor vessel normalization.” (opens the source at this quote in a new tab)

Effects on cancer stem cell phenotype, migration, and invasion in gastric cancer models

“Treatment with human DLL4 therapeutic antibody (anti-hDLL4) or ABL001 slightly reduced GC cell growth in monolayer culture; however, they significantly inhibited cell growth in 3D-culture, suggesting a reduction in the cancer stem cell population. Treatment with anti-hDLL4 or ABL001 also decreased GC cell migration and invasion.” (opens the source at this quote in a new tab)

“Interestingly, the combination treatment of ABL001 with irinotecan synergistically reduced the GC burden in both xenograft and orthotopic mouse models.” (opens the source at this quote in a new tab)

Clinical pharmacodynamic or target-engagement biomarkers

No evidence found.